BackDrugs Made In America Acquisition Ordinary Shares Overview

Drugs Made In America Acquisition Ordinary Shares Receivables

Latest receivables for DMAA: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Drugs Made In America Acquisition Ordinary Shares Receivables History

Loading

Drugs Made In America Acquisition Ordinary Shares vs. peers: Receivables Comparison

Loading

Drugs Made In America Acquisition Ordinary Shares Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Drugs Made In America Acquisition Ordinary Shares (DMAA) FAQ

The latest receivables for DMAA is $0 as of June 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside Drugs Made In America Acquisition Ordinary Shares's historical trend and sector peers before judging valuation or financial health.

Over the past year, DMAA's receivables moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Drugs Made In America Acquisition Ordinary Shares's operating scale or balance-sheet position.

A receivables figure of $0 for DMAA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting DMAA's receivables ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.